Nancy A. West
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nancy A. West has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Thomas H. Mosley
From the Department of Preventive Medicine (N.A.W.) and Department of Medicine (B.G.W., T.H.M.), Division of Geriatrics, University of Mississippi Medical Center, Jackson; Department of Neurology (D.S.K.), Mayo Clinic, Rochester, MN; Department of Radiology (D.K.S.), University of Washington Medical Center, Seattle; and Division of Public Health Sciences (L.H.C.), Wake Forest School of Medicine, Winston-Salem, NC
2 shared publicationsB. Gwen Windham
From the Department of Preventive Medicine (N.A.W.) and Department of Medicine (B.G.W., T.H.M.), Division of Geriatrics, University of Mississippi Medical Center, Jackson; Department of Neurology (D.S.K.), Mayo Clinic, Rochester, MN; Department of Radiology (D.K.S.), University of Washington Medical Center, Seattle; and Division of Public Health Sciences (L.H.C.), Wake Forest School of Medicine, Winston-Salem, NC
1 shared publicationBeverly G. Windham
Division of Geriatrics, Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi
1 shared publicationDavid S. Knopman
From the Department of Preventive Medicine (N.A.W.) and Department of Medicine (B.G.W., T.H.M.), Division of Geriatrics, University of Mississippi Medical Center, Jackson; Department of Neurology (D.S.K.), Mayo Clinic, Rochester, MN; Department of Radiology (D.K.S.), University of Washington Medical Center, Seattle; and Division of Public Health Sciences (L.H.C.), Wake Forest School of Medicine, Winston-Salem, NC
1 shared publicationDean K. Shibata
From the Department of Preventive Medicine (N.A.W.) and Department of Medicine (B.G.W., T.H.M.), Division of Geriatrics, University of Mississippi Medical Center, Jackson; Department of Neurology (D.S.K.), Mayo Clinic, Rochester, MN; Department of Radiology (D.K.S.), University of Washington Medical Center, Seattle; and Division of Public Health Sciences (L.H.C.), Wake Forest School of Medicine, Winston-Salem, NC
1 shared publicationElizabeth Selvin
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
1 shared publication
Latest Publications
- 26 February 2019
- Published by Wolters Kluwer Health in Neurology
- Vol. 92 (9) , e917-e923
Neuroimaging findings in midlife and risk of late-life dementia over 20 years of follow-up
Objective To examine the association between neuroimaging features in a predominantly middle-aged cohort and risk of late-life dementia. Methods Cerebral MRI was performed on 1,881 individuals with no history of stroke from the Atherosclerosis Risk in Communities Study cohort in 1993 to 1995. White matter hyperintensities (WMH), ventricular size, and sulcal size were graded on a semiquantitative scale, and presence of silent cerebral infarcts was identified. In 2011 to 2013, dementia was determined from neuropsychological testing, informant interview, hospital ICD-9 codes, and death certificate dementia codes. Cox regression was used to evaluate associations between MRI findings and dementia. Results Over 20 years of follow-up, dementia developed in 279 participants (14.8%). High-grade WMH and high-grade ventricular size were independently associated with increased dementia risk (hazard ratio [HR] for WMH 1.62, 95% confidence interval [CI] 1.14–2.30; HR for ventricular size 1.46, 95% CI 1.06–2.03). There was an increased risk of dementia for diabetic participants with silent infarcts (HR 2.56, 95% CI 1.23–5.31) but not among nondiabetic participants (HR 0.87, 95% CI 0.56–1.37). Each 1-unit increase in the total number of high-grade cerebral abnormalities at baseline (count values range 0–4) showed increased dementia risk, with a considerably higher risk among diabetic participants (HR for diabetes mellitus 1.97, 95% CI 1.44–2.69; HR for no diabetes mellitus 1.20, 95% CI 1.03–1.39). Conclusion In adults without evidence of clinical stroke, MRI-detected WMH and ventricular enlargement in midlife may represent markers of brain injury that increase risk for later-life cognitive impairment. The presence of diabetes mellitus may modify the association between silent infarcts and dementia.
- 26 February 2019
- Published by Wolters Kluwer Health in Neurology
- Vol. 92 (9) , e917-e923
Neuroimaging findings in midlife and risk of late-life dementia over 20 years of follow-up
Objective To examine the association between neuroimaging features in a predominantly middle-aged cohort and risk of late-life dementia. Methods Cerebral MRI was performed on 1,881 individuals with no history of stroke from the Atherosclerosis Risk in Communities Study cohort in 1993 to 1995. White matter hyperintensities (WMH), ventricular size, and sulcal size were graded on a semiquantitative scale, and presence of silent cerebral infarcts was identified. In 2011 to 2013, dementia was determined from neuropsychological testing, informant interview, hospital ICD-9 codes, and death certificate dementia codes. Cox regression was used to evaluate associations between MRI findings and dementia. Results Over 20 years of follow-up, dementia developed in 279 participants (14.8%). High-grade WMH and high-grade ventricular size were independently associated with increased dementia risk (hazard ratio [HR] for WMH 1.62, 95% confidence interval [CI] 1.14–2.30; HR for ventricular size 1.46, 95% CI 1.06–2.03). There was an increased risk of dementia for diabetic participants with silent infarcts (HR 2.56, 95% CI 1.23–5.31) but not among nondiabetic participants (HR 0.87, 95% CI 0.56–1.37). Each 1-unit increase in the total number of high-grade cerebral abnormalities at baseline (count values range 0–4) showed increased dementia risk, with a considerably higher risk among diabetic participants (HR for diabetes mellitus 1.97, 95% CI 1.44–2.69; HR for no diabetes mellitus 1.20, 95% CI 1.03–1.39). Conclusion In adults without evidence of clinical stroke, MRI-detected WMH and ventricular enlargement in midlife may represent markers of brain injury that increase risk for later-life cognitive impairment. The presence of diabetes mellitus may modify the association between silent infarcts and dementia.
- 1 April 2018
- Published by Wolters Kluwer Health in Alzheimer Disease & Associated Disorders
- Vol. 32 (2) , 131-136
The PPARG Pro12Ala Polymorphism and 20-year Cognitive Decline
Previous reports suggest race/ethnic and sex heterogeneity in the association between the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma (PPARG) gene and cognitive decline. Tests of verbal memory, processing speed, and verbal fluency and a composite global Z-score were used to assess cognitive performance longitudinally in a large (n=11,620) biracial cohort of older adults in the Atherosclerosis Risk in Communities Neurocognitive Study from midlife to older age. Linear mixed models were used to estimate associations between the Ala12 allele and cognitive performance over 20 years of follow-up. Heterogeneity was present for rate of cognitive decline as measured by the global Z-score by race, sex, and Ala12 allele status (P=0.01 for 4-way interaction term: race×sex×time×Ala12 carrier status). Stratified analysis showed a significantly increased rate of global cognitive decline over the 20-year follow-up for carriers of the Ala12 allele compared with noncarriers among black male individuals (−0.92 SD decline vs. −0.57 SD; P=0.02) but not among black female, white male, or white female individuals. Decline in global cognitive function among black male Ala12 carriers was primarily driven by decline in verbal memory. Our data underscore the context-dependent association between the Pro12Ala polymorphism and cognitive decline, specifically race/ethnic background and sex.
- 1 April 2018
- Published by Wolters Kluwer Health in Alzheimer Disease & Associated Disorders
- Vol. 32 (2) , 131-136
The PPARG Pro12Ala Polymorphism and 20-year Cognitive Decline
Previous reports suggest race/ethnic and sex heterogeneity in the association between the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma (PPARG) gene and cognitive decline. Tests of verbal memory, processing speed, and verbal fluency and a composite global Z-score were used to assess cognitive performance longitudinally in a large (n=11,620) biracial cohort of older adults in the Atherosclerosis Risk in Communities Neurocognitive Study from midlife to older age. Linear mixed models were used to estimate associations between the Ala12 allele and cognitive performance over 20 years of follow-up. Heterogeneity was present for rate of cognitive decline as measured by the global Z-score by race, sex, and Ala12 allele status (P=0.01 for 4-way interaction term: race×sex×time×Ala12 carrier status). Stratified analysis showed a significantly increased rate of global cognitive decline over the 20-year follow-up for carriers of the Ala12 allele compared with noncarriers among black male individuals (−0.92 SD decline vs. −0.57 SD; P=0.02) but not among black female, white male, or white female individuals. Decline in global cognitive function among black male Ala12 carriers was primarily driven by decline in verbal memory. Our data underscore the context-dependent association between the Pro12Ala polymorphism and cognitive decline, specifically race/ethnic background and sex.
- 1 March 2017
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 65 (6) , 1282-1288
Adiposity, Change in Adiposity, and Cognitive Decline in Mid‐ and Late Life
Objectives: To examine associations between adiposity and adiposity change (loss, stable, gain) and subsequent longitudinal cognitive performance in African Americans in mid and late life. Design: Cohort study using linear mixed models. Setting: Genetic Epidemiology Network of Arteriopathy. Participants: African‐American sibships with hypertension in Jackson, Mississippi (N = 1,108). Measurements: Waist circumference and body mass index ( BMI ) were measured at two examinations 5 years apart. Stable adiposity was defined as values within 5% of the first measure. A composite cognitive Z ‐score was derived from individual cognitive test Z ‐scores at two study visits 6 years apart. Results: Larger waist circumference was associated with greater rate of cognitive decline during follow‐up (beta = −0.0009 per year, P = .001); BMI , change in waist circumference, and change in BMI were not associated with rate of decline. Loss of adiposity in midlife was associated with higher cognitive Z ‐scores in middle‐aged individuals, and loss of adiposity in late life was associated with lower Z ‐scores in older adults ( P = .01 for interaction between waist circumference and age; P = .04 for interaction between BMI and age). Simultaneous inclusion of waist circumference and BMI in the cross‐sectional model suggested an association between larger waist circumference and poorer cognitive performance (beta = −0.009, P = .006) and between higher BMI and better cognitive performance (beta = 0.014, P = .06). Conclusion: The results suggested a differential pattern of the relationship between adiposity and cognition according to age (mid‐ or late life) and regional distribution of adiposity.
- 1 March 2017
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 65 (6) , 1282-1288
Adiposity, Change in Adiposity, and Cognitive Decline in Mid‐ and Late Life
Objectives: To examine associations between adiposity and adiposity change (loss, stable, gain) and subsequent longitudinal cognitive performance in African Americans in mid and late life. Design: Cohort study using linear mixed models. Setting: Genetic Epidemiology Network of Arteriopathy. Participants: African‐American sibships with hypertension in Jackson, Mississippi (N = 1,108). Measurements: Waist circumference and body mass index ( BMI ) were measured at two examinations 5 years apart. Stable adiposity was defined as values within 5% of the first measure. A composite cognitive Z ‐score was derived from individual cognitive test Z ‐scores at two study visits 6 years apart. Results: Larger waist circumference was associated with greater rate of cognitive decline during follow‐up (beta = −0.0009 per year, P = .001); BMI , change in waist circumference, and change in BMI were not associated with rate of decline. Loss of adiposity in midlife was associated with higher cognitive Z ‐scores in middle‐aged individuals, and loss of adiposity in late life was associated with lower Z ‐scores in older adults ( P = .01 for interaction between waist circumference and age; P = .04 for interaction between BMI and age). Simultaneous inclusion of waist circumference and BMI in the cross‐sectional model suggested an association between larger waist circumference and poorer cognitive performance (beta = −0.009, P = .006) and between higher BMI and better cognitive performance (beta = 0.014, P = .06). Conclusion: The results suggested a differential pattern of the relationship between adiposity and cognition according to age (mid‐ or late life) and regional distribution of adiposity.
- 6 October 2016
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 46 (1) , 96-100
Cognitive decline and the PPAR-γ Pro12Ala genotype: variation by sex and ethnicity
We investigated the association between the peroxisome proliferator-activated receptor (PPAR)-gamma Pro12Ala polymorphism and cognitive decline in older adults. participants from a population-based cohort of older Hispanic and non-Hispanic white adults (n = 492) were administered the Mini Mental State Examination (MMSE), a multi-domain cognitive screening tool, and the Behavioral Dyscontrol Scale (BDS), a measure of executive cognitive function, at baseline and at follow-up, an average of 22 months later. Multiple linear regression was used to investigate the association between the two cognitive test scores and the Pro12Ala polymorphism. at baseline, presence of the Ala12 allele was not significantly associated with MMSE score (P = 0.62) nor with BDS score (P = 0.85). Heterogeneity was present for cognitive decline as measured by the MMSE among ethnic, sex and Ala12 allele status (P = 0.04 for three-way interaction term). Stratification by the cross-classification of sex and ethnicity revealed significantly greater declines in MMSE score among male Hispanic carriers of the Ala12 allele compared to male Hispanic non-carriers (decline = 4.0 versus 1.6 points; P = 0.02). A significant difference in decline between Ala12 carriers and non-carriers was not present among the other sex/ethnic groups. carriers of the PPAR-γ Ala12 allele showed greater cognitive decline compared to non-carriers as detected by the MMSE but the risk varied across sex and ethnic groups. Male Ala12 carriers of Hispanic origin may be a high-risk group for cognitive decline.
- 6 October 2016
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 46 (1) , 96-100
Cognitive decline and the PPAR-γ Pro12Ala genotype: variation by sex and ethnicity
We investigated the association between the peroxisome proliferator-activated receptor (PPAR)-gamma Pro12Ala polymorphism and cognitive decline in older adults. participants from a population-based cohort of older Hispanic and non-Hispanic white adults (n = 492) were administered the Mini Mental State Examination (MMSE), a multi-domain cognitive screening tool, and the Behavioral Dyscontrol Scale (BDS), a measure of executive cognitive function, at baseline and at follow-up, an average of 22 months later. Multiple linear regression was used to investigate the association between the two cognitive test scores and the Pro12Ala polymorphism. at baseline, presence of the Ala12 allele was not significantly associated with MMSE score (P = 0.62) nor with BDS score (P = 0.85). Heterogeneity was present for cognitive decline as measured by the MMSE among ethnic, sex and Ala12 allele status (P = 0.04 for three-way interaction term). Stratification by the cross-classification of sex and ethnicity revealed significantly greater declines in MMSE score among male Hispanic carriers of the Ala12 allele compared to male Hispanic non-carriers (decline = 4.0 versus 1.6 points; P = 0.02). A significant difference in decline between Ala12 carriers and non-carriers was not present among the other sex/ethnic groups. carriers of the PPAR-γ Ala12 allele showed greater cognitive decline compared to non-carriers as detected by the MMSE but the risk varied across sex and ethnic groups. Male Ala12 carriers of Hispanic origin may be a high-risk group for cognitive decline.
- 13 December 2015
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 25 (5) , 539-544
Prescription opioid exposures and adverse outcomes among older adults
Purpose: A high prevalence of chronic pain and high rates of polypharmacy among older adults suggest that this age group may be particularly susceptible to unintentional misuse of prescription opioids. We examined recent trends in misuse of prescription opioids and associated medical outcomes among older‐aged adults (60+ years) and compared the patterns with trends among younger‐aged adults (20–59 years).Methods: Linear regression trend analysis was used to analyze 57 681 misuse cases reported to participating US poison centers during 2006–2014.Results: Population rates of misuse of prescription opioids were higher for older adults than for younger adults, and this disparity increased over time. Rates among the older ages increased each year, although the rate of increase slowed over time (p < 0.0001 for negative quadratic trend). In contrast, among the younger adults, there was a significant negative quadratic trend in population rates (p < 0.0001) with a rise in rates during 2006–2010 followed by a decline during 2011–2014. Rates of serious medical outcomes among the older ages followed an increasing linear trend (p < 0.0001); in contrast, rates among younger adults rose and fell during the period, with recent rates trending downward (p < 0.0001 for quadratic trend).Conclusions: Recent increases in rates of misuse of prescription opioids and associated unfavorable medical outcomes among older adults have important implications as the USA undergoes a rapid expansion of its elderly population. Copyright © 2015 John Wiley & Sons, Ltd.
- 13 December 2015
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 25 (5) , 539-544
Prescription opioid exposures and adverse outcomes among older adults
Purpose: A high prevalence of chronic pain and high rates of polypharmacy among older adults suggest that this age group may be particularly susceptible to unintentional misuse of prescription opioids. We examined recent trends in misuse of prescription opioids and associated medical outcomes among older‐aged adults (60+ years) and compared the patterns with trends among younger‐aged adults (20–59 years).Methods: Linear regression trend analysis was used to analyze 57 681 misuse cases reported to participating US poison centers during 2006–2014.Results: Population rates of misuse of prescription opioids were higher for older adults than for younger adults, and this disparity increased over time. Rates among the older ages increased each year, although the rate of increase slowed over time (p < 0.0001 for negative quadratic trend). In contrast, among the younger adults, there was a significant negative quadratic trend in population rates (p < 0.0001) with a rise in rates during 2006–2010 followed by a decline during 2011–2014. Rates of serious medical outcomes among the older ages followed an increasing linear trend (p < 0.0001); in contrast, rates among younger adults rose and fell during the period, with recent rates trending downward (p < 0.0001 for quadratic trend).Conclusions: Recent increases in rates of misuse of prescription opioids and associated unfavorable medical outcomes among older adults have important implications as the USA undergoes a rapid expansion of its elderly population. Copyright © 2015 John Wiley & Sons, Ltd.